VIRX(Delisted)
Viracta Therapeutics·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 0
Bearish signal 1
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About VIRX
Viracta Therapeutics, Inc.
A biopharmaceutical company that developing targeted inhibitors for the treatment of blood and solid cancers
2533 S Coast Hwy 101, Suite 210, Cardiff, California 92007
--
Viracta Therapeutics, Inc., was incorporated in Delaware on February 10, 1998. Its subsidiaries are mainly located in South San Francisco, California. Viracta is a precision oncology company that targets virus-related malignancies. Viracta's proprietary investigational drug, Nanatinostat, is currently being evaluated in Phase 2 clinical trials in EBV-positive lymphoma in combination with the antiviral drug valganciclovir as an oral combination therapy. Viracta is applying this induced synthetic lethal approach to malignancies associated with EBV, such as nasopharyngeal cancer, gastric cancer and viral-associated cancers.
Company Financials
EPS
VIRX has released its 2024 Q3 earnings. EPS was reported at -0.27, versus the expected -0.24, missing expectations. The chart below visualizes how VIRX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
